Holen Sie sich die Stockscreener-App
15.18
3.19%
-0.50
Vorhandelsmarkt:
15.16
-0.02
-0.13%
Adma Biologics Inc Aktie (ADMA) Neueste Nachrichten
ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance - Finviz
Westfield Capital Management Co. LP Takes $74.87 Million Position in ADMA Biologics Inc $ADMA - MarketBeat
New ADMA Biologics CFO Takes Helm As Valuation Gap Draws Focus - Yahoo Finance
Decoding ADMA Biologics Inc (ADMA): A Strategic SWOT Insight - GuruFocus
ADMA Biologics Inc (ADMA) Q4 2025 Earnings Call Highlights: Stro - GuruFocus
ADMA Biologics Inc earnings beat by $0.03, revenue fell short of estimates - Investing.com
ADMA Biologics (ADMA) Reports Strong 2025 Results and Positive O - GuruFocus
ADMA Biologics Reports Strong Q4 2025 Earnings and Positive Outlook - Intellectia AI
ADMA Biologics Q4 2025 Earnings Call Transcript - MarketBeat
ADMA forecasts $635M revenue for 2026 as ASCENIV drives margin expansion and new supply deals extend growth runway - MSN
ADMA Biologics Q4 Earnings Call Highlights - Yahoo Finance
ADMA Biologics Says Brad Tade Is Retiring As Chief Financial Officer - TradingView
Earnings call transcript: ADMA Biologics reports strong Q4 2025 growth - Investing.com
ADMA Biologics (NASDAQ:ADMA) Issues Quarterly Earnings Results - MarketBeat
ADMA BIOLOGICS, INC. SEC 10-K Report - TradingView
(ADMA) ADMA Biologics Expects 2026 Revenue to Exceed $635M, vs. FactSet Est of $633.8M - marketscreener.com
Adma Biologics: Fourth Quarter Financial Overview - Bitget
ADMA Biologics Announces CFO Transition and Leadership Change - TipRanks
Adma Biologics: Q4 Earnings Snapshot - Barchart.com
ADMA Biologics CFO Brad Tade retires; Terry Kohler promoted to CFO - TradingView
ADMA Biologics, Inc. Announces Chief Financial Officer Changes - marketscreener.com
ADMA Biologics earnings up next: Can momentum match lofty targets? By Investing.com - Investing.com Canada
ADMA Biologics earnings up next: Can momentum match lofty targets? - Investing.com India
Aug Outlook: Is ADMA Biologics Inc attractive for institutional investorsGap Down & Weekly High Return Stock Opportunities - baoquankhu1.vn
Aug Outlook: Whats the beta of ADMA Biologics Inc stockMarket Activity Recap & Short-Term Swing Trade Alerts - baoquankhu1.vn
ADMA Biologics to Announce Q4 Earnings on February 25 - Intellectia AI
Preview: ADMA Biologics's Earnings - Benzinga
What To Expect From ADMA Biologics Inc (ADMA) Q4 2025 Earnings - GuruFocus
ADMA Biologics Inc (ADMA) Stock Analysis: A Biotech With A 59.42% Potential Upside - DirectorsTalk Interviews
ADMA Biologics (ADMA) to Release Quarterly Earnings on Monday - MarketBeat
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Aberdeen Group plc Increases Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
ADMA Biologics CEO Sale And Options Activity Versus Valuation And Momentum - Yahoo Finance
ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 - Quiver Quantitative
Adam Grossman, president of Adma Biologics, sells $337,679 in shares By Investing.com - Investing.com South Africa
Adam Grossman, president of Adma Biologics, sells $337,679 in shares - Investing.com
(ADMA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
ADMA Biologics Inc (ADMA) Stock Analysis: Unlocking a 59.52% Upside in the Biotech Arena - DirectorsTalk Interviews
Public Sector Pension Investment Board Acquires 116,867 Shares of ADMA Biologics Inc $ADMA - MarketBeat
Assessing ADMA Biologics (ADMA) Valuation After Recent Share Price Rebound - Sahm
Market Leaders: Can ADMA Biologics Inc outperform in the next rallyJuly 2025 Analyst Calls & Risk Controlled Stock Alerts - baoquankhu1.vn
What are ADMA Biologics Inc.’s growth leversJuly 2025 Review & Community Trade Idea Sharing Platform - mfd.ru
Aug Movers: What is the cash position of REPXJuly 2025 Weekly Recap & Target Return Focused Picks - baoquankhu1.vn
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note - Nasdaq
Navellier & Associates Inc. Has $176,000 Stake in ADMA Biologics Inc $ADMA - MarketBeat
New York State Common Retirement Fund Decreases Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
Principal Financial Group Inc. Cuts Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
ADMA Biologics Inc (ADMA) Stock Analysis: Attractive 56.22% Upside Potential For Investors - DirectorsTalk Interviews
Renaissance Group LLC Has $7.57 Million Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
(ADMA) Risk Channels and Responsive Allocation - Stock Traders Daily
Assessing ADMA Biologics (ADMA) Valuation After Growing Analyst Optimism On Earnings And Plasma Therapy Pipeline - Yahoo Finance
Homestead Advisers Corp Has $2.91 Million Position in ADMA Biologics Inc $ADMA - MarketBeat
Is ADMA Biologics (ADMA) Pricing Reflect A Potential Gap To DCF And P/E Estimates - Yahoo Finance
ADMA Biologics (NASDAQ:ADMA) Seems To Use Debt Rather Sparingly - 富途牛牛
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Federated Hermes Inc. Reduces Holdings in ADMA Biologics Inc $ADMA - MarketBeat
ADMA Biologics Inc (ADMA) Stock Analysis: Unpacking A 48% Potential Upside - DirectorsTalk Interviews
Universal Beteiligungs und Servicegesellschaft mbH Cuts Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
ADMA Biologics Inc $ADMA Shares Bought by Thrivent Financial for Lutherans - MarketBeat
Is it worth investing in Adma Biologics (ADMA) based on Wall Street's bullish views? - MSN
Aug Movers: Does Assured Guaranty Ltd have strong EBITDA marginsJuly 2025 Gainers & Reliable Price Action Trade Plans - baoquankhu1.vn
Returns Recap: Is Celularity Inc Equity Warrant forming higher highs and higher lowsWeekly Market Outlook & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
ADMA Biologics Inc $ADMA Shares Sold by Lisanti Capital Growth LLC - MarketBeat
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views? - Finviz
0.11%
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):